WSJ Context Free Reporting on Drug Costs
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - January 5, 2016 Category: Pharmaceuticals Source Type: blogs
BIO asks, "What's in a name?
The Biotechnology Industry Organization changed its name to the Biotechnology Innovation Organization. The group will continue using the "BIO" acronym. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - January 5, 2016 Category: Pharmaceuticals Source Type: blogs
CDC's Opioid Reset
This morning the CDC will ask the National Center for Injury Prevention and Control's Board of Scientific Counselors to appoint a new work group to review the agency's draft guideline for prescribing opioids for chronic pain. It's the next step in CDC's effort to address complaints over the secretive way in which the initial draft was developed. Public comments on the draft guideline are due Jan. 13, and the new group will be tasked with reviewing those, too. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - January 5, 2016 Category: Pharmaceuticals Source Type: blogs
Spotlight vs Blind Spot
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - January 4, 2016 Category: Pharmaceuticals Source Type: blogs
It Was a Very Good Year. Really.
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 30, 2015 Category: Pharmaceuticals Source Type: blogs
Price/Value: A Happy New Year?
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 30, 2015 Category: Pharmaceuticals Source Type: blogs
Congress Seeks CDC Sunshine
Things are heating up at the CDC. The agency’s lack of transparency regarding their development of opioid prescribing guidelines has drawn the attention of the House Committee on Oversight and Government Reform. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 22, 2015 Category: Pharmaceuticals Source Type: blogs
Opioids Rocket Docket
To paraphrase Homer Hickam (of "October Sky" fame), “A rocket docket won't fly unless somebody lights the fuse.” Here are my comments to the CDC’s docket Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain: (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 18, 2015 Category: Pharmaceuticals Source Type: blogs
AMERICAN Psycho
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 17, 2015 Category: Pharmaceuticals Source Type: blogs
Woodcock's 2016 Priorities
CDER Director Janet Woodcock, speaking Monday at the FDA/CMS Summit in Washington, DC, outlined 2015’s achievements and a number of the agency’s top priorities for 2016, particularly as CDER, with its $1.2 billion budget, continues to work with Congress on legislation like the House-passed 21st Century Cures Act. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 17, 2015 Category: Pharmaceuticals Source Type: blogs
Congress Ignores The Real Prescription Drug Problem
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 10, 2015 Category: Pharmaceuticals Source Type: blogs
Partners For Better Care: Social Activism for Access
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 8, 2015 Category: Pharmaceuticals Source Type: blogs
Let's Invest in the Health of 9-11 Survivors
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 8, 2015 Category: Pharmaceuticals Source Type: blogs
CDC Feels the Pain
A panel set up to coordinate pain research across the federal government is blasting a CDC proposal to rein in opioid prescribing set for release next month.The level of evidence cited to support the guidelines, which are non-binding on physicians, "is low to very low and that's a problem," said Sharon Hertz, FDA's director of the Division of Anesthesia, Analgesia and Addiction Products. AHRQ health scientist Richard Ricciardi called the recommendations "ridiculous" and "an embarrassment to the government." (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - December 4, 2015 Category: Pharmaceuticals Source Type: blogs
Healthcare Reform? Don't Give Up the Ship.
The Department of Health and Human Services (HHS) insisted Tuesday that the individual health insurance markets under the Affordable Care Act (ACA) have a strong future, despite a warning from one of the nation's biggest insurers that it may drop out of the markets due to unsustainable losses. "Public companies do not pursue programs that cost the company hundreds of millions of dollars in losses," Pitts said. "For that, rocket science is not required." (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - November 25, 2015 Category: Pharmaceuticals Source Type: blogs
